

| Package | Price per Dose | Price | |
|---|---|---|---|
| 180 pills | €2,19 | €526,64 €394,98 Free shipping | |
| 120 pills | €2,44 | €389,43 €292,07 Free shipping | |
| 90 pills | €2,57 | €308,71 €231,53 Free shipping | |
| 60 pills | €2,75 | €219,93 €164,94 | |
| 30 pills | €3,03 | €121,05 €90,79 | |
| 10 pills | €3,63 | €48,41 €36,31 | |
| 180 pills | €3,22 | €772,82 €579,61 Free shipping | |
| 120 pills | €3,25 | €520,59 €390,44 Free shipping | |
| 90 pills | €3,42 | €409,60 €307,20 Free shipping | |
| 60 pills | €4,06 | €324,85 €243,64 Free shipping | |
| 30 pills | €4,24 | €169,48 €127,11 | |
| 10 pills | €4,84 | €64,55 €48,41 | |
| 180 pills | €2,07 | €498,39 €373,79 Free shipping | |
| 120 pills | €2,30 | €367,23 €275,42 Free shipping | |
| 90 pills | €2,56 | €306,69 €230,02 Free shipping | |
| 60 pills | €2,85 | €228,00 €171,00 | |
| 30 pills | €3,18 | €127,10 €95,33 | |
| 20 pills | €4,27 | €112,98 €84,73 | |
| 10 pills | €4,56 | €60,52 €45,39 | |
| 180 pills | €4,12 | €986,71 €740,03 Free shipping | |
| 120 pills | €4,33 | €692,10 €519,08 Free shipping | |
| 90 pills | €4,81 | €577,09 €432,81 Free shipping | |
| 60 pills | €5,08 | €407,59 €305,69 Free shipping | |
| 30 pills | €6,28 | €252,21 €189,16 Free shipping | |
| 10 pills | €6,81 | €90,78 €68,09 |
Disclaimer: This information is for patients in the Netherlands and is not a substitute for professional medical advice. Always consult a pharmacist or physician for personalized guidance. Prescription requirements may vary locally.
Candida infections are among the most common fungal infections encountered in routine medical practice; fluconazole is a triazole antifungal used to treat a broad range of Candida infections. Fluconazole belongs to the azole class of antifungals and acts by inhibiting fungal enzymes involved in membrane synthesis. This action disrupts the integrity of fungal cell membranes and inhibits growth. The medication is designed to reach sites of infection through systemic circulation, including mucosal surfaces and, in some circumstances, the central nervous system.
Diflucan is marketed in the Netherlands under the international nonproprietary name fluconazole and the brand name Diflucan. The active substance is fluconazole, which is rapidly absorbed when taken by mouth. It is generally well tolerated when used appropriately and under medical supervision. For some patients, a pharmacist will review potential interactions with other medicines and the patient’s medical history before dispensing.
Administration may occur in hospital or at home, depending on the infection type and treatment plan. In general, the aim is to achieve effective concentrations at the site of infection while minimising adverse effects. The Netherlands follows guidelines that emphasise careful consideration of liver function, drug interactions, and patient-specific factors when selecting antifungal therapy. Check the official patient leaflet and consult a healthcare professional if any questions arise.
The following information provides a detailed overview of approved uses, practical considerations, safety points, and patient guidance for Diflucan. It is intended to support informed, shared decision-making and safe use in routine care. If any aspect is unclear, the official product leaflet or a pharmacist should be consulted for clarification.
Note: This section uses precise medical terminology with explanations in parentheses to aid understanding. The tone remains professional and impersonal, as would be expected in a patient information leaflet produced by a clinical pharmacist.
The content is written to assist patients, caregivers, and healthcare professionals in the Netherlands, with attention to practical issues such as dosing strategies, safety, and how Diflucan fits within broader antifungal therapy. While every effort is made to present accurate information, readers should verify details with the official leaflet and a healthcare professional before starting treatment.
The pharmaceutical landscape for antifungal therapy is continually updated; recommendations may evolve with new evidence, regulatory changes, or national guidelines. When in doubt, seek guidance from a pharmacist or physician.
Diflucan is used for infections caused by susceptible Candida species as well as for selected systemic fungal infections. The principal focus is on mucosal infections such as those affecting the mouth, throat, and genitals, and on certain systemic infections where the organism remains susceptible to fluconazole. The aim of therapy is to eradicate the fungus while minimising relapse and adverse effects.
In addition to approved indications, fluconazole is sometimes employed off-label under specialist supervision in contexts where other antifungal options are not suitable or available. Off-label use may include certain fungal infections of the urinary tract or specific prophylactic scenarios in immunocompromised patients. If off-label use is contemplated, it is undertaken with careful assessment of risks, benefits, and alternative therapies.
When treating vaginal candidiasis, fluconazole can be chosen as a systemic option depending on patient preferences, accessibility, and prior treatment history. For mucosal candidiasis involving the oropharynx or esophagus, the drug is used to achieve adequate tissue concentrations and durable antifungal activity. In some cases, especially with immune compromise or resistant organisms, additional or alternative antifungal medicines may be considered under specialist guidance.
For systemic infections such as candidemia or certain meningitis scenarios caused by susceptible organisms, fluconazole may be part of a broader therapeutic plan that also includes other antifungal agents or supportive care. The choice of therapy depends on the severity of illness, site of infection, fungal susceptibility, and patient-specific factors. Consultation with infectious disease specialists may be appropriate in complex cases.
In the Netherlands, treatment decisions reflect local formulary guidelines and regulatory approvals. The information provided here is intended to support informed discussion with a healthcare professional. If there is any uncertainty about indications, consult the official leaflet or contact a pharmacist for clarification.
Fluconazole exerts its antifungal effect by inhibiting fungal cytochrome P450 enzyme lanosterol 14α-demethylase (a key enzyme in ergosterol synthesis). This enzyme is responsible for the conversion of lanosterol to ergosterol, a sterol essential for maintaining fungal cell membrane structure and function. Inhibition leads to increased cell membrane permeability and impaired fungal growth, with the effect described as fungistatic in many organisms. (Fungistatic means that the drug inhibits the growth or replication of fungi rather than directly killing them.)
The resulting shortage of ergosterol disrupts membrane integrity and alters membrane-bound transport processes, which hampers fungal replication and survival. Because humans do not use ergosterol in the same way for cell membranes, fluconazole can selectively target fungal cells with a tolerable safety margin in many patients. This selectivity is an important pharmacological feature of azole antifungals as a class.
Pharmacokinetically, fluconazole is characterized by relatively high oral bioavailability and good systemic distribution, including penetration into several body compartments such as the cerebrospinal fluid when meningeal inflammation is present. It is metabolised in the liver to a lesser extent than many other antifungals and is excreted largely by the kidneys unchanged, although some metabolites are formed. Dose adjustments may be required in renal impairment to maintain appropriate drug exposure. Drug interactions can occur via shared metabolic pathways, particularly with drugs that affect hepatic cytochrome P450 enzymes.
Fluconazole demonstrates concentration‑dependent activity against many Candida species, with higher drug levels providing sustained antifungal exposure at infection sites. The pharmacodynamic profile supports once‑daily dosing for many indications, but the exact regimen is determined by the site and severity of infection, organism susceptibility, and patient characteristics. In all cases, the goal is to achieve consistent drug exposure that suppresses fungal growth while minimising toxicity.
Level of tissue penetration, half-life, and clearance are all relevant for planning duration of therapy and monitoring. In practice, patient factors such as liver function tests, renal function, and potential interactions with other medications are reviewed prior to and during treatment. If any unexpected symptoms arise, medical evaluation should be sought promptly.
Oral fluconazole is absorbed reliably from the gastrointestinal tract and distributes widely in body fluids and tissues. The drug penetrates well into saliva, vaginal secretions, and interstitial fluid, which supports efficacy in mucosal infections. Fluconazole crosses the blood–brain barrier to reach the central nervous system when appropriate, enabling treatment of meningitis caused by susceptible organisms. The elimination half‑life is prolonged in certain patient populations, and renal excretion is a major route of clearance.
Potential drug interactions arise because fluconazole inhibits certain hepatic enzymes involved in drug metabolism, though the extent varies with dose and co‑administered medications. Interactions may affect the levels of concomitant drugs such as certain anticoagulants, immunosuppressants, anticonvulsants, or antidiabetic agents. A medication review by a pharmacist or physician is advised when initiating therapy with fluconazole in the context of polypharmacy. In such cases, monitoring for adverse effects or loss of therapeutic effect of other medicines is prudent.
Common adverse effects include gastrointestinal symptoms (nausea, abdominal discomfort), headache, and rash. Hepatic adverse effects can occur and require monitoring of liver function tests, especially with prolonged use or in patients with pre‑existing liver disease. Rare severe reactions, including hepatotoxicity and hypersensitivity responses, necessitate immediate medical attention. If jaundice, dark urine, persistent vomiting, or severe rash develops, urgent medical assessment is warranted.
Fluconazole is generally avoided or used with caution in patients with significant hepatic impairment, and dose adjustments may be required in those with renal impairment. Breastfeeding is a consideration since fluconazole is excreted into breast milk; a decision to breastfeed during treatment should be made in consultation with a healthcare professional, balancing benefits and potential risks to the infant. The safety of fluconazole in pregnancy is dose‑dependent and requires careful medical supervision; in many situations alternative antifungal options may be considered unless the potential benefit justifies use.
All prescribing decisions should reflect local guidelines, the official product leaflet, and patient‑specific factors. If any uncertainties arise about interactions with current medications, the patient should be advised to consult a pharmacist before starting therapy or during the course of treatment.
Oral tablets or oral suspension may be used, depending on the clinical scenario and patient ability to swallow. Dose forms and strength are selected to optimise absorption and patient adherence in the Netherlands and may be adjusted for age, weight, kidney or liver function, and infection type. The choice of dose and duration is guided by clinical guidelines, organism susceptibility, and patient response.
For uncomplicated vaginal candidiasis, a single 150 mg tablet is a commonly recommended option in some guidelines, whereas other regimens may be used based on prior treatment, recurrence risk, and patient preference. For mucosal candidiasis involving the mouth, throat, or esophagus, treatment may be longer and tailored to the site and severity of infection. Systemic infections often require longer courses and, in complex cases, collaboration with infectious diseases specialists is advised.
Oral administration is usually taken with a full glass of water and may be taken with or without food, depending on tolerance. Tablets should be swallowed whole; if the formulation is an alternate dosage form, instructions for use are provided in the patient information leaflet. If a dose is missed, the plan followed by a clinician should guide the next steps; do not double up without professional advice. Completion of the prescribed course is important even if symptoms improve.
A pharmacy professional can review potential interactions with other medicines and provide patient‑specific advice on timing relative to meals or other medications. If a complex dosing schedule is required, a printable plan or reminder system may be helpful to maintain adherence. In all cases, any adjustments should be made under medical supervision.
In cases of renal impairment, adjustments to dosing frequency or amount may be required to achieve appropriate exposure and limit toxicity. Duration of therapy may be shortened or extended depending on clinical response and microbiological data. If signs of liver injury or unusual fatigue occur during therapy, prompt medical consultation is advised.
Diflucan is contraindicated in individuals with known hypersensitivity to fluconazole or other azole antifungals. Severe hepatic dysfunction or acute liver injury is a critical consideration when evaluating the risk of treatment with fluconazole. In the Netherlands, patients with significant hepatic disease are usually managed with alternative antifungal strategies or with careful monitoring if hepatic impairment is mild.
Allergic reactions, including rash, itching, swelling, or difficulty breathing, require immediate medical attention. A history of liver disease or liver enzyme abnormalities should be discussed with a clinician before initiating therapy, and liver function tests may be conducted during treatment if indicated. A potential risk of drug interactions exists, particularly with medications that affect the hepatic cytochrome P450 system or QT interval; adjustments to other therapies may be needed.
Pregnancy is a sensitive consideration for antifungal therapy. Fluconazole use during pregnancy should be carefully weighed against potential benefits and risks, and the lowest effective dose should be considered when therapy is deemed essential. Breastfeeding mothers should seek guidance on infant exposure, as fluconazole can pass into breast milk.
Renal or hepatic impairment may necessitate dose adjustments or alternative therapies. In patients with severe renal impairment, fluconazole is predominantly excreted unchanged in urine, and clearance may be reduced; thus, monitoring and potential dose modification are warranted. In the context of liver disease, the risk of hepatotoxicity requires vigilance for symptoms such as right upper quadrant discomfort, jaundice, or unusual fatigue.
Adverse effects monitoring is recommended for prolonged courses or in patients with comorbidity. If serious adverse events occur, treatment should be reassessed promptly and appropriate medical care obtained. The official patient leaflet contains a comprehensive list of potential adverse effects and interactions.
In elderly patients, pharmacokinetic changes may alter drug exposure; clinical judgment should guide dosing adjustments and monitoring frequency. In those with hepatic impairment, careful evaluation of liver function and potential alternative agents is advised, given the risk of hepatotoxicity. For patients with renal impairment, dose adjustments may be required to maintain safe and effective drug levels.
Used as part of a broader antifungal strategy, fluconazole therapy often requires coordination with other medications, particularly in patients undergoing chemotherapy, transplantation, or long‑term antibiotic therapy. Drug–drug interactions can influence antifungal efficacy and safety, necessitating careful medication reconciliation at every healthcare contact.
Immune‑compromised individuals, such as those with advanced HIV infection or post‑organ transplantation, may require closer clinical monitoring for breakthrough infections or adverse reactions. Prophylactic use should only occur under specialist supervision with ongoing evaluation of risk versus benefit.
In the community setting, education on adherence, recognition of adverse effects, and timely reporting of symptoms supports safe use. Patients should be advised to store the medication as directed and to seek advice if there are any doubts about dosing or duration.
With regard to formulation accessibility, Diflucan tablets are typically available by prescription in the Netherlands, and pharmacy staff can provide tailored information about storage, expiry dates, and safe handling. If a dose is inadvertently omitted, guidance should be sought from a healthcare professional rather than self‑adjusting the regimen.
Overall, safe and effective use depends on accurate indication, appropriate dosing, awareness of interactions, and ongoing clinical assessment. The official patient leaflet should be consulted for detailed safety information and for indications that require medical supervision.
| Drug | Primary use (typical indications) | Notable considerations |
|---|---|---|
| Diflucan (fluconazole) | Mucosal Candida infections; some systemic infections; cryptococcal infections when appropriate | Good oral bioavailability; crosses CSF; potential interactions with other drugs |
| Itraconazole | Broad-spectrum fungal infections including some moulds and dermatophytes | Variable absorption with gastric pH; potential cardiac effects; different drug interactions |
| Voriconazole | Serious invasive fungal infections, including Aspergillus spp. | Higher risk of hepatotoxicity and visual disturbances; more monitorable adverse effects |
The following questions cover common patient concerns about fluconazole therapy, including how quickly it works, what to do if a dose is missed, interactions with food and drink, the typical duration of treatment, when to contact a clinician, and considerations for long‑term use. Where possible, precise dosing is avoided unless there is a universally standard dose. If in doubt, consult the official leaflet or a pharmacist.
Answers are written in a patient‑friendly style while preserving medical accuracy. The information is not a substitute for professional medical advice. If symptoms persist or worsen, seek medical attention promptly.
Careful consideration is given to safety, tolerability, and the balance of benefits and risks in various patient groups. The guidance does not replace clinical judgment or regulatory requirements in the Netherlands.
Readers are encouraged to discuss any questions with a pharmacist, who can review current medications, allergies, and health conditions to identify potential risks and tailor advice accordingly.
When seeking urgent help due to severe symptoms, seek urgent medical attention. If there is uncertainty about whether fluconazole is appropriate, a clinician should be consulted before starting treatment.
Fluconazole use in pregnancy requires careful assessment of benefits and risks. The lowest effective dose should be used only if clearly needed, and alternative approaches may be considered. Consultation with a clinician is advised before use in pregnancy or while planning pregnancy.
If a dose is missed, the recommended action is to take it as soon as remembered unless the next dose is due soon. Do not double the dose to catch up. If there is any uncertainty, contact a pharmacist or clinician for tailored guidance.
Fluconazole can interact with certain other medicines, including some anticoagulants and immunosuppressants. Food generally does not cause major interactions, but some people notice stomach upset when taking the medicine on an empty stomach. A pharmacist should be informed about all medicines, including over‑the‑counter products and supplements, to assess potential interactions.
Duration depends on the site and severity of infection and how the patient responds to therapy. Some mucosal infections may respond within days, while others require a longer course. The exact length of treatment is determined by a clinician and may be adjusted based on clinical progress and laboratory data.
Most people can continue normal activities, but dizziness or fatigue may occur in some cases. If such symptoms are present, caution is advised when engaging in tasks requiring alertness.
Severe or persistent side effects warrant prompt medical evaluation. Severe rash, signs of liver injury (such as yellowing of the skin or eyes, dark urine, severe abdominal pain), or allergic reactions require urgent attention.
Long‑term prophylactic use is generally reserved for specific high‑risk conditions under specialist supervision. Continuous therapy necessitates regular monitoring for adverse effects and drug interactions.
Food and drink generally do not require avoidance beyond standard dietary considerations. Some individuals may experience gastrointestinal discomfort with certain formulations, but there are no universal dietary prohibitions. Discuss any concerns with a pharmacist if a reaction is suspected.
The most commonly reported effects are mild gastrointestinal symptoms, headaches, and occasional skin rashes. Most side effects are mild and resolve with continued therapy or following dose adjustment. Notify a clinician if symptoms persist or worsen.
Antacid use does not typically necessitate avoidance, but the timing of administration may influence absorption in some cases. If a PPI or similar medication is prescribed, consult a pharmacist or clinician to ensure the regimen accounts for potential interactions and absorption considerations.
If symptoms persist or reappear after completing therapy, a clinician should reassess the diagnosis and review susceptibility testing if available. Additional antifungal therapy or alternative agents may be considered based on organism, site of infection, and patient factors.
Fluconazole has approved pediatric indications in many settings, with dosing adjusted for age and weight. A clinician will determine appropriate therapy for younger patients, and dosing should be guided by professional medical advice rather than adult recommendations alone.
Alcohol consumption is not universally contraindicated with fluconazole, but excessive intake may worsen side effects such as liver stress or abdominal symptoms in some individuals. It is prudent to limit alcohol while on therapy and to discuss personal health conditions with a clinician if there are concerns.
Leftover antifungal tablets should not be used beyond the expiration date. Do not share medication with others. Dispose of unused medicine according to local guidelines or pharmacist advice.
14–21 days. Free from €182,34 .
5–9 days. €27,35
−10% when paying with cryptocurrency.
−10% on all repeat orders.
All orders are packed in neutral, unbranded boxes with no product name on the outside.
